BOLD Stock Overview
A clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Boundless Bio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.35 |
| 52 Week High | US$15.24 |
| 52 Week Low | US$2.33 |
| Beta | 0 |
| 11 Month Change | -22.19% |
| 3 Month Change | -37.17% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -83.51% |
Recent News & Updates
Shareholder Returns
| BOLD | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -21.9% | 2.4% | 2.2% |
| 1Y | n/a | 16.2% | 31.7% |
Return vs Industry: Insufficient data to determine how BOLD performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how BOLD performed against the US Market.
Price Volatility
| BOLD volatility | |
|---|---|
| BOLD Average Weekly Movement | 12.5% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: BOLD's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: BOLD's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 72 | Zach Hornby | boundlessbio.com |
Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA. Its lead product candidate is BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers. The company is also developing BBI-825, an oral inhibitor of ribonucleotide reductase, which is in Phase 1/2 clinical trial in cancer patients with resistance gene amplifications; and ecDTx 3 program targeting a kinesin involved with the cellular mechanism for segregation of ecDNA.
Boundless Bio, Inc. Fundamentals Summary
| BOLD fundamental statistics | |
|---|---|
| Market cap | US$57.31m |
| Earnings (TTM) | -US$61.06m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.9x
P/E RatioIs BOLD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BOLD income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$61.06m |
| Earnings | -US$61.06m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.74 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did BOLD perform over the long term?
See historical performance and comparison